The Future of Immunotherapies in Advanced/Recurrent Endometrial Cancer Treatment

Video

Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.

CN_RO360_EC_SGO_Seg06_POPULATIONS
Current Time 0:00
Duration 6:23
Loaded: 0%
Stream Type LIVE
Remaining Time 6:23
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Recent Videos
    Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
    Data Support Niraparib Combo as First-Line Maintenance in Ovarian Cancer
    ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
    ADCs May Preserve Responses in Later Lines of Ovarian Cancer Therapy
    Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
    Rina-S Elicited Responses With/Without FRα Expression in Ovarian Cancer
    Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
    Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
    Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
    Exploring CDK4/6 Endocrine Therapy for Low-Grade Serous Ovarian Cancer
    The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
    Evaluating Frontline Treatment Options for Low-Grade Serous Ovarian Cancer
    Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
    Distinguishing Low-Grade Serous Ovarian Cancer From Other Ovarian Cancer Types
    Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
    Optimizing Surgery With New AI Technologies in Breast and Ovarian Cancer
    Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
    Reduced Time and Improved Outcomes in Cancer Surgeries with MarginCall
    Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
    Fluorescent-Based Imaging with AI Can Improve Surgery in Breast and Ovarian Cancer
    Related Content
    Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

    Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

    Tim Cortese
    March 26th 2025
    Article

    The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.

    Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

    Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

    Kathleen N. Moore, MD, MS
    March 17th 2025
    Podcast

    Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

    Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

    Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

    Russ Conroy
    March 19th 2025
    Article

    Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

    Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

    Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

    John Paul Diaz, MD
    November 4th 2024
    Podcast

    Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

    Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

    Niraparib/Bevacizumab Maintenance Prolongs Response in Pretreated Ovarian Cancer

    Ariana Pelosci
    March 18th 2025
    Article

    Results from the NIRVANA-R trial found niraparib/bevacizumab maintenance yielded positive activity in pretreated ovarian cancer.

    Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.

    Immunotherapy Sustains Responses in Radiated Endometrial/Cervical Cancer

    Roman Fabbricatore
    March 18th 2025
    Article

    Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.